

12/24/03

f AR

cc: Jkunuz@annurev.org (Jean Kunz -Annual Reviews)
To: gubins@annurev.org (Sam Gubins-Annual Reviews)
From: lederberg@mail.rockefeller.edu
Fcc: /jm/AR
Subject: Ann Rev Pathology; - Cancer Biology; Dec 13 ExCom

Dear Sam:

I respond somewhat belatedly to the work book for the recent ExCom. I'm sorry this is so tardy, but I've had a very heavy travel schedule this fall(Japan one trip; bangkok-Beijing another), and that's wreaked havoc with many good intentions.

It's quite late in the day, but I have some misgivings about AR-Path, mainly that a major competitor was not even mentioned. There are frequent reviews (called Perspective, Clinical Implications of Basic Research, Review Article, ...) in almost every issue of the New England Journal. Less formidable are "Mechanisms of Disease" in Lancet.

Maybe the guild doesn't want to acknowledge all that as "pathology"; but judge for yourself the depth of overlap.

It might be a great convenience to have a annual collection of these articles in book form.

There are contra's to my remarks in the visibility of the proposed editors; but I hope there is time to consult a bit more broadly.

ASIP sponsorship might count for a lot; but I'd also seek informed assurance from an insider just what standing that society has.

=====

I'm somewhat happier about AR Cancer Research; but there too is formidable competition from Advances in Cancer Research. However, I know that the NCI/director* and many workers in the field are eager to build cancer biology as a bridging discipline, and there probably is room for another review entry.

I know Andy von Eschenbach* pretty well, and he is quite dedicated to better "translational" integration in Cancer Biology. I'd be willing to pass on a case statement exploring the possibility of some subsidy from NCI.
